GlassScriptPhysician profile
Urvashi Nath
NPI 1336990175
$2,825.16
in general payments reported to CMS, 2019-2025
29 companies · $1,982 in 2025
The $1,982 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $843 · 2025: $1,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,825.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $246.81 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Radius Health, INC. | $198.87 | 2024-2025 | |
| Lilly USA, LLC | $188.91 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Ibsa Pharma INC. | $186.61 | 2024-2025 | Licart, Tirosint, Flector |
| Xeris Pharmaceuticals, INC. | $182.65 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Medtronic, INC. | $180.36 | 2024-2025 | Minimed 780g |
| Abbott Laboratories | $176.00 | 2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $168.89 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $162.56 | 2024-2025 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.34 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $114.86 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $106.81 | 2024-2025 | |
| Abbvie INC. | $102.21 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $86.33 | 2024-2025 | |
| Corcept Therapeutics | $82.30 | 2025 | Korlym |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $72.34 | 2024-2025 | Jatenzo |
| Recordati_rare_diseases_inc. | $58.45 | 2025 | Isturisa |
| Dexcom, INC. | $54.18 | 2025 | Dexcom G6 Transmitter |
| Alvogen INC | $52.34 | 2024-2025 | Teriparatide |
| Amneal Pharmaceuticals LLC | $46.66 | 2024 | Unithroid |
| Beta Bionics, INC. | $43.46 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $33.96 | 2025 | Twiist |
| Almatica Pharma LLC | $25.29 | 2025 | Teriparatide |
| Neurocrine Biosciences, INC. | $24.47 | 2024 | |
| Alexion Pharmaceuticals, INC. | $23.13 | 2025 | Strensiq |
| Madrigal Pharmaceuticals | $22.97 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $22.56 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $18.04 | 2024 | Crysvita |
| Acella Pharmaceuticals, LLC | $15.80 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Urvashi Nath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.